Sulfacetamide
(Synonyms: 磺胺醋酰; Sulphacetamide) 目录号 : GC38686
A sulfonamide antibiotic
Cas No.:144-80-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sulfacetamide is a sulfonamide antibiotic that is bacteriostatic against Gram-positive and Gram-negative bacteria. It inhibits dihydropteroate synthase (IC50 = 9.6 ?M), blocking the synthesis of dihydrofolic acid, and also inhibits bacterial 4-aminobenzoic acid , which is required for the synthesis of folic acid.1
1.Prabhu, V., Lui, H., and King, J.Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamidesPhytochemistry45(1)23-27(1997)
| Cas No. | 144-80-9 | SDF | |
| 别名 | 磺胺醋酰; Sulphacetamide | ||
| Canonical SMILES | CC(NS(=O)(C1=CC=C(N)C=C1)=O)=O | ||
| 分子式 | C8H10N2O3S | 分子量 | 214.24 |
| 溶解度 | DMSO : 43mg/mL | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6677 mL | 23.3383 mL | 46.6766 mL |
| 5 mM | 0.9335 mL | 4.6677 mL | 9.3353 mL |
| 10 mM | 0.4668 mL | 2.3338 mL | 4.6677 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Treatment of seborrheic dermatitis: a comprehensive review
J Dermatolog Treat 2019 Mar;30(2):158-169.PMID:29737895DOI:10.1080/09546634.2018.1473554.
Seborrheic dermatitis (SD) is a chronic, recurring inflammatory skin disorder that manifests as erythematous macules or plaques with varying levels of scaling associated with pruritus. The condition typically occurs as an inflammatory response to Malassezia species and tends to occur on seborrheic areas, such as the scalp, face, chest, back, axilla, and groin areas. SD treatment focuses on clearing signs of the disease; ameliorating associated symptoms, such as pruritus; and maintaining remission with long-term therapy. Since the primary underlying pathogenic mechanisms comprise Malassezia proliferation and inflammation, the most commonly used treatment is topical antifungal and anti-inflammatory agents. Other broadly used therapies include lithium gluconate/succinate, coal tar, salicylic acid, selenium sulfide, sodium Sulfacetamide, glycerin, benzoyl peroxide, aloe vera, mud treatment, phototherapy, among others. Alternative therapies have also been reported, such as tea tree oil, Quassia amara, and Solanum chrysotrichum. Systemic therapy is reserved only for widespread lesions or in cases that are refractory to topical treatment. Thus, in this comprehensive review, we summarize the current knowledge on SD treatment and attempt to provide appropriate directions for future cases that dermatologists may face.
Rosacea Management
Skin Appendage Disord 2016 Sep;2(1-2):26-34.PMID:27843919DOI:10.1159/000446215.
Background: Rosacea is a chronic inflammatory skin condition associated with four distinct subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular. Purpose: To review the different kinds of management for all subtypes. Methods: We divided rosacea management into three main categories: patient education, skin care, and pharmacological/procedural interventions. Results: Flushing is better prevented rather than treated, by avoiding specific triggers, decreasing transepidermal water loss by moisturizers, and blocking ultraviolet light. Nonselective β-blockers and α2-adrenergic agonists decrease erythema and flushing. The topical α-adrenergic receptor agonist brimonidine tartrate 0.5% reduces persistent facial erythema. Intradermal botulinum toxin injection is almost safe and effective for the erythema and flushing. Flashlamp-pumped dye, potassium-titanyl-phosphate and pulsed-dye laser, and intense pulsed light are used for telangiectasias. Metronidazole 1% and azelaic acid 15% cream reduce the severity of erythema. Both systemic and topical remedies treat papulopustules. Systemic remedies include metronidazole, doxycycline, minocycline, clarithromycin and isotretinoin, while topical remedies are based on metronidazole 0.75%, azelaic acid 15 or 20%, sodium Sulfacetamide, ivermectin 1%, permethrin 5%, and retinoid. Ocular involvement can be treated with oral or topical antibacterial. Rhinophyma can be corrected by dermatosurgical procedures, decortication, and various types of lasers. Conclusion: There are many options for rosacea management. Patients may have multiple subtypes, and each phase has its own treatment.
Synthesis of a new magnetic Sulfacetamide-Ethylacetoacetate hydrazone-chitosan Schiff-base for Cr(VI) removal
Int J Biol Macromol 2022 Dec 1;222(Pt A):1465-1475.PMID:36113599DOI:10.1016/j.ijbiomac.2022.09.081.
In this study, a novel magnetic organic-inorganic composite was fabricated. Chitosan, Sulfacetamide and ethylacetoacetae were used to prepare a new Sulfacetamide-Ethylacetoacetate hydrazone-chitosan Schiff-base (SEH-CSB) with a variety of active sites that capable of forming coordinate covalent bonds with Cr(VI). This was followed by modification of the formed SHE-CSB with NiFe2O4 to obtain the magnetic Chitosan-Schiff-base composite (NiFe2O4@SEH-CSB). NiFe2O4@SEH-CSB was characterized using FTIR, zeta potential, SEM, VSM and XPS. Results clarified that SHE played a crucial role in the removal of Cr(VI). The removal of Cr(VI) on NiFe2O4@SEH-CSB was found to be more fitted to pseudo-second order kinetics model and Freundlich isotherm. Besides, the maximum adsorption capacity of NiFe2O4@SEH-CSB towards Cr(VI) was found to be 373.61 mg/g. The plausible mechanism for the removal of Cr(VI) by NiFe2O4@SEH-CSB composite suggested the domination of coulombic interaction, outer-sphere complexation, ion-exchange, surface complexation and coordinate-covalent bond pathways. The magnetic property enabled easy recycling of NiFe2O4@SEH-CSB composite for seven sequential cycles.
Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium Sulfacetamide and sulfur formulations
Cutis 2004 Jan;73(1 Suppl):29-33.PMID:14959943doi
The combination of sodium Sulfacetamide and sulfur is unique in the rosacea armamentarium because of its dual use as topical therapy and therapeutic cleanser. Several formulations of Sulfacetamide 10% and sulfur 5% are now available as topical lotions and cleansers. The Sulfacetamide/sulfur cleansers serve as adjunctive therapy by providing additive effects to other topical and oral therapies for rosacea with favorable tolerability and cosmetic appeal.
The use of sodium Sulfacetamide in dermatology
Cutis 2015 Aug;96(2):128-30.PMID:26367751doi
Sodium Sulfacetamide is effective in the management of a variety of inflammatory facial dermatoses and often is used in combination with sulfur for a synergistic effect. Adverse effects from sodium Sulfacetamide are rare and generally are limited to mild application-site reactions. This agent is contraindicated in any patient with known hypersensitivity to sulfonamides.